Literature DB >> 29699715

Atherosclerosis and clonal hematopoyesis: A new risk factor.

José A Páramo Fernández1.   

Abstract

Recent research has revealed that clonal hematopoyesis of indeterminate potential (CHIP) characterized by the acquisition of somatic mutations in hematopoietic stem cells, is not only a common age-related disorder and a premalignant condition, but it is also associated with the development of atherosclerotic vascular diseases. Mutations in DNMT3A, TET2 and ASXL1 were each individually associated with coronary heart disease, stroke and coronary calcification. Therefore, CHIP emerges as a new risk factor for atherosclerotic vascular pathologies and its detection may be relevant as a new therapeutic target in order to modify the natural course of the disease.
Copyright © 2018 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Aterosclerosis; Atherosclerosis; Calcificación coronaria; Cardiovascular diseases; Clonal hematopoiesis of indeterminate potential; Coronary calcification; Enfermedades cardiovasculares; Hematopoyesis clonal de potencial indeterminado

Mesh:

Substances:

Year:  2018        PMID: 29699715     DOI: 10.1016/j.arteri.2018.03.001

Source DB:  PubMed          Journal:  Clin Investig Arterioscler        ISSN: 0214-9168


  3 in total

Review 1.  Clinical consequences of clonal hematopoiesis of indeterminate potential.

Authors:  David P Steensma
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  Clinical consequences of clonal hematopoiesis of indeterminate potential.

Authors:  David P Steensma
Journal:  Blood Adv       Date:  2018-11-27

3.  Naoxintong Retards Atherosclerosis by Inhibiting Foam Cell Formation Through Activating Pparα Pathway.

Authors:  Zeng Wang; Huairui Shi; Huan Zhao; Zhen Dong; Buchang Zhao; Xinyu Weng; Rongle Liu; Xiao Li; Kai Hu; Yunzeng Zou; Aijun Sun; Junbo Ge
Journal:  Curr Mol Med       Date:  2018       Impact factor: 2.222

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.